Quote this publication Share Print

PROCYSBI (cysteamine), metabolism medicinal product

RARE DISEASE - Update
Opinions on drugs - Posted on Nov 08 2016

Reason for request

Re-assessment of the improvement in actual benefit

Maintenance of minor clinical added value in the treatment of proven nephropathic cystinosis by comparison with CYSTAGON.

 

  • PROCYSBI has Marketing Authorisation in the treatment of proven nephropathic cystinosis.
  • The presentation takes the form of prolonged-release gastro-resistant hard capsules, which need to be taken only once every 12 hours. However, better compliance with PROCYSBI relative to CYSTAGON (same active ingredient but with immediate release) cannot be formally established.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Therapeutic use

-

Contact Us

Évaluation des médicaments